BR112019028180A2 - anticorpos com domínios funcionais na região do cotovelo entre os domínios variável e constante - Google Patents

anticorpos com domínios funcionais na região do cotovelo entre os domínios variável e constante Download PDF

Info

Publication number
BR112019028180A2
BR112019028180A2 BR112019028180-0A BR112019028180A BR112019028180A2 BR 112019028180 A2 BR112019028180 A2 BR 112019028180A2 BR 112019028180 A BR112019028180 A BR 112019028180A BR 112019028180 A2 BR112019028180 A2 BR 112019028180A2
Authority
BR
Brazil
Prior art keywords
antibody
antigen
domain
polypeptide chain
binding fragment
Prior art date
Application number
BR112019028180-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Antonio Lanzavecchia
Luca PICCOLI
Original Assignee
Institute For Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Research In Biomedicine filed Critical Institute For Research In Biomedicine
Publication of BR112019028180A2 publication Critical patent/BR112019028180A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019028180-0A 2017-07-31 2018-07-30 anticorpos com domínios funcionais na região do cotovelo entre os domínios variável e constante BR112019028180A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/069357 2017-07-31
PCT/EP2017/069357 WO2019024979A1 (en) 2017-07-31 2017-07-31 FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
PCT/EP2018/070640 WO2019025391A1 (en) 2017-07-31 2018-07-30 ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN

Publications (1)

Publication Number Publication Date
BR112019028180A2 true BR112019028180A2 (pt) 2020-07-07

Family

ID=59626578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019028180-0A BR112019028180A2 (pt) 2017-07-31 2018-07-30 anticorpos com domínios funcionais na região do cotovelo entre os domínios variável e constante

Country Status (13)

Country Link
US (1) US12331108B2 (enExample)
EP (1) EP3661962A1 (enExample)
JP (2) JP7297734B2 (enExample)
KR (1) KR20200032738A (enExample)
CN (1) CN111094341A (enExample)
AU (1) AU2018311032B2 (enExample)
BR (1) BR112019028180A2 (enExample)
CA (1) CA3069265A1 (enExample)
EA (1) EA202090364A1 (enExample)
IL (1) IL272303A (enExample)
MX (1) MX2020001080A (enExample)
SG (1) SG11201911658QA (enExample)
WO (2) WO2019024979A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
KR102879521B1 (ko) 2018-03-22 2025-11-03 서피스 온콜로지, 엘엘씨 항-il-27 항체 및 이의 용도
CA3104274A1 (en) * 2018-05-10 2019-11-14 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
WO2019229193A1 (en) 2018-05-30 2019-12-05 Institute For Research In Biomedicine Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
WO2021158521A1 (en) 2020-02-03 2021-08-12 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
HRP20231031T1 (hr) 2020-02-26 2023-12-22 Vir Biotechnology, Inc. Protutijela protiv sars-cov-2
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20240059757A1 (en) 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
BR112022022523A2 (pt) 2020-05-08 2023-01-10 Vir Biotechnology Inc Anticorpos contra sars-cov-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
BR112022025229A2 (pt) 2020-06-12 2023-03-07 Vir Biotechnology Inc Terapias de anticorpos para infecção por sars-cov-2
WO2022067269A2 (en) 2020-09-28 2022-03-31 Humabs Biomed Sa Antibodies against sars-cov-2
CN113307869B (zh) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
JP2023551668A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド インフルエンザのノイラミニダーゼに対する広域中和抗体
MX2023005653A (es) 2020-11-23 2023-07-31 Vir Biotechnology Inc Anticuerpos contra los virus de la influenza a.
TW202235105A (zh) 2020-11-23 2022-09-16 美商維爾生物科技股份有限公司 抗流感抗體及其組合
JP2023550785A (ja) 2020-11-25 2023-12-05 ヴィア・バイオテクノロジー・インコーポレイテッド 複数のベータコロナウイルスに結合する抗体
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
US20240076411A1 (en) * 2020-12-30 2024-03-07 WuXi Biologics Ireland Limited Multispecific antigen binding proteins
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
IL308148A (en) * 2021-05-07 2023-12-01 Senti Biosciences Inc Chimeric receptors and methods of use thereof
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
CA3230613A1 (en) 2021-09-01 2023-03-09 Daren J. AUSTIN Antibody therapies for sars-cov-2 infection in pediatric subjects
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
TWI892695B (zh) 2021-12-10 2025-08-01 美商歐米諾斯公司 結合ｍａｓｐ－２的絲氨酸蛋白酶結構域的治療性抗體及其用途
EP4663656A2 (en) 2022-03-10 2025-12-17 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2023230445A2 (en) 2022-05-23 2023-11-30 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
KR20250169612A (ko) 2023-04-10 2025-12-03 비르 바이오테크놀로지, 인코포레이티드 다수의 사르베코바이러스에 결합하는 항체
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
EP2350128B1 (en) 2008-10-22 2014-10-01 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
MX2015008446A (es) * 2012-12-28 2016-10-26 Abbvie Inc Composiciones de proteinas de union multivalentes.
US20140235476A1 (en) * 2012-12-28 2014-08-21 Abbvie, Inc. Multivalent binding protein compositions and methods for identifying variants of same
JP6262768B2 (ja) 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
EP3288975A1 (en) * 2015-04-29 2018-03-07 Institute for Research in Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
IL256315B2 (en) * 2015-06-18 2023-12-01 Vib Vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
JP7058219B2 (ja) * 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
CA3104274A1 (en) * 2018-05-10 2019-11-14 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides

Also Published As

Publication number Publication date
SG11201911658QA (en) 2020-03-30
US12331108B2 (en) 2025-06-17
AU2018311032B2 (en) 2025-01-23
MX2020001080A (es) 2020-08-06
EA202090364A1 (ru) 2020-06-26
US20200325220A1 (en) 2020-10-15
WO2019025391A1 (en) 2019-02-07
CA3069265A1 (en) 2019-02-07
KR20200032738A (ko) 2020-03-26
CN111094341A (zh) 2020-05-01
AU2018311032A1 (en) 2019-12-05
IL272303A (en) 2020-03-31
JP2020528758A (ja) 2020-10-01
EP3661962A1 (en) 2020-06-10
JP2023123588A (ja) 2023-09-05
JP7297734B2 (ja) 2023-06-26
WO2019025391A9 (en) 2020-02-13
WO2019024979A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
US12331108B2 (en) Antibodies with functional domains in the elbow region between variable and constant domain
US11618776B2 (en) Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
CN112512594A (zh) 经由基因调节多肽的条件性核定位的基因调节
JP2020188762A (ja) 細胞の細胞質への分子の送達のための構築物
CN114026123A (zh) 靶向活性基因编辑剂及使用方法
KR20230162013A (ko) Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질
US20210254106A1 (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
US20250122264A1 (en) Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
JP2022524221A (ja) 標的指向活性遺伝子編集剤及び使用方法
TW202319397A (zh) NKp46結合多肽及其用途
WO2021115456A1 (en) BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
EA046243B1 (ru) Антитела с функциональными доменами в области изгиба между вариабельным и константым доменом
HK40029066A (en) Antibodies with functional domains in the elbow region between variable and constant domain
TW202509064A (zh) 靶向干擾素α融合蛋白及使用方法
HK40090466A (zh) 包含表达嵌合受体的细胞的药物组合物
TW202510911A (zh) Ｔ細胞接合劑掩蔽分子
HK40068271A (en) Targeted active gene editing agent and methods of use
HK40040001A (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements